The authors describe considerations and best practices for meeting drug substance uniformity.
Sushil Abraham
Advertisement
Articles by Sushil Abraham
The authors present lessons learned from a case study of the transfer of a cell culture biotherapeutic process to a CMO.
Advertisement
Latest Updated Articles
Practical Considerations for Demonstrating Drug Substance UniformityPublished: April 1st 2011 | Updated:
Successful Technology Transfer, Process Validation, and Partnership with a CMOPublished: March 2nd 2011 | Updated:
Advertisement
Advertisement
